FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden hours per response: 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Meirav Udi	2. Date of Requiring (Month/Da 07/26/20	Statement y/Year)	3. Issuer Name and Ticker or Trading Symbol <u>Candel Therapeutics</u> , <u>Inc.</u> [CADL]						
(Last) (First) (Middle) C/O CANDEL THERAPEUTICS,			4. Relationship of Reporting Issuer (Check all applicable)	Person(s) to 10% Owner Other (specify below)			5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person		
INC. 117 KENDRICK ST., SUITE 450	_		X Director Officer (give title below)			(Ch			
(Street) NEEDHAM MA 02494	_								
(City) (State) (Zip)									
Table I - Non-Derivative Securities Beneficially Owned									
1. Title of Security (Instr. 4)			2. Amount of Securities Beneficially Owned (Instr. 4)	Form: D (D) or Ir			Nature of Indirect Beneficial vnership (Instr. 5)		
Common Stock			48,822)				
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)									
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securiti Underlying Derivative Security (Instr. 4)		Convers		e Form:	6. Nature of Indirect Beneficial Ownership (Instr.	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security		Direct (D) or Indirect (I) (Instr. 5)	5)	
Stock Option (Right to Buy)	(1)	08/17/2028	Common Stock	12,205	1.46		D		
Stock Option (Right to Buy)	(2)	06/18/2029	Common Stock	71,198	1.46		D		
Stock Option (Right to Buy)	(2)	12/14/2030	Common Stock	16,274	1.55		D		
Stock Option (Right to Buy)	(2)	06/23/2031	Common Stock	16,274	6.6	4	D		

Explanation of Responses:

- 1. 25% of this option vested and became exercisable on January 1, 2019, with the remainder vesting in three substantially equal monthly installments thereafter.
- 2. This option is fully vested and exercisable as of the date hereof.

Remarks:

<u>/s/ Udi Meirav</u> <u>07/26/2021</u>

** Signature of Reporting

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.